Developer docs
API playgroundTry for free, no card

Search company profiles

Resonea

Full company profile

uuid0003n45

Namestring
Resonea
Legal namestring
Resonea, Inc.
Websiteurl
resonea.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Resonea, Inc. was a Delaware-incorporated, Scottsdale-headquartered healthcare technology company that developed sleep testing diagnostic technology aimed at accelerating the diagnosis of sleep disorders, particularly sleep apnea. The company's core offering centered on acoustic flow analysis and microphone data channels that enabled smartphone-based home sleep testing, positioning it to address the widespread underdiagnosis of sleep apnea through a consumer-accessible diagnostic format. The technology leveraged the ubiquity of smartphone microphones to capture respiratory acoustic signatures, eliminating the need for traditional in-lab polysomnography or dedicated hardware for initial screening.

The company operated from approximately 2016 to mid-2024, raising approximately $9.65 million across multiple funding rounds including an initial $4 million round in October 2016, a $250,000 Arizona Commerce Authority grant in January 2018, a $30,000 Flinn Foundation grant in February 2020, a $2.37 million round in September 2020, and a $5 million exempt offering (with $3 million sold) filed via SEC Form D in January 2022. The company was led by CEO Ruchir Sehra and Joe Cooper as Chief of Strategy and Corporate Development, operating with a team of 11-50 employees. Resonea held a US-only operating geography based on its Delaware incorporation and Scottsdale base.

In July 2024, Resonea's sleep testing diagnostic technology — including its acoustic flow analysis and smartphone-based home sleep testing capabilities — was acquired by EnsoData, a US-based healthcare technology and software firm. The transaction represented a technology/asset acquisition rather than an entity acquisition, and the company's website domain subsequently appears to have been repurposed, indicating that Resonea ceased independent operations following the divestiture of its core technology assets to EnsoData.

Short descriptiontext

Resonea, Inc. was a Scottsdale-based healthcare technology company that developed smartphone-based home sleep apnea diagnostic tools using acoustic flow analysis and microphone data channels. Its core diagnostic technology was acquired by EnsoData in July 2024.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersScottsdale, United States
HQ citystring
Scottsdale
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
sleep apnea diagnostics, home sleep testing, acoustic flow analysis, sleep health technology, digital health screening
Industry2 codes
PRIMARYHLAHAGAB
Sleep Diagnostics & Monitoring (PSG/Home Sleep Testing, Actigraphy)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAHACAL
Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Sleep Diagnostics Software
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Resonea developed sleep testing diagnostic technology that enabled home-based sleep apnea screening using acoustic flow analysis and microphone data channels captured via smartphones. The technology was designed to accelerate the diagnosis of sleep disorders and address the widespread underdiagnosis of sleep apnea through accessible, smartphone-enabled home testing rather than traditional in-lab polysomnography.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Resonea was a healthcare technology company that developed sleep testing diagnostic technology for sleep apnea screening. The company's primary offering was sleep testing diagnostic technology that utilized acoustic flow and microphone data channels to enable smartphone-based home sleep testing. In July 2024, Resonea's sleep testing technology was acquired by EnsoData, indicating Resonea no longer operates independently in this space.

Product and service1 record
1Sleep Testing Diagnostic Technology
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierNotableTypeTechnology or IntegrationAnnounced on2024-07-01
Description

EnsoData, a US-based healthcare technology and software firm, acquired Resonea's sleep testing diagnostic technology in July 2024. The acquisition was intended to enhance EnsoData's sleep apnea screening methods and home sleep testing capabilities through acoustic flow and microphone data channels.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Dominant incumbent in sleep-disordered breathing with CPAP devices, masks, and the myAir platform; an adjacent peer because it influences the diagnostic-to-therapy pathway that any HST technology must integrate with.

TypeDirect peer
Description

AI-based sleep scoring and diagnostics platform that directly acquired Resonea's acoustic flow technology in 2024 to enhance its home sleep testing offering. Most direct comparable given the asset transfer and overlapping product category.

TypeBroad incumbent
Description

Large incumbent offering CPAP, home sleep testing (Alice line), and connected sleep health platforms, providing a broad competitive backdrop for any home-based sleep apnea screening technology.

TypeDirect peer
Description

Global sleep diagnostics company offering PSG and home sleep testing systems used in clinical sleep medicine; comparable in product category and end customers.

TypeEmerging player
Description

Smart ring maker whose Oura Ring tracks sleep patterns and has begun exploring chronic condition features; represents the consumer wearable axis that could pressure smartphone-based screening.

TypeDirect peer
Description

Manufacturer of the Nox T3 and other home sleep testing/recording systems used by sleep labs and clinicians, making it a direct peer in ambulatory sleep diagnostics hardware.

TypeDirect peer
Description

Maker of the WatchPAT home sleep apnea testing device. Direct competitor in the home-based sleep apnea diagnostic category with established clinical evidence and regulatory clearances.

TypeEmerging player
Description

Consumer health hardware maker (Sleep Analyzer, ScanWatch) that has moved into home sleep apnea detection, partially overlapping with Resonea's consumer-grade, smartphone-adjacent screening approach.

TypeEmerging player
Description

Sleep technology company developing EEG-based headbands and digital sleep diagnostics, with overlap in home-based sleep measurement and analytics.

TypeDirect peer
Description

Provides home sleep testing devices and cloud-based sleep diagnostics services for clinicians, directly competing with Resonea's home-based sleep apnea screening offering.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Resonea

Sleep Diagnostics Softwareresonea.com

Resonea, Inc. was a Scottsdale-based healthcare technology company that developed smartphone-based home sleep apnea diagnostic tools using acoustic flow analysis and microphone data channels. Its core diagnostic technology was acquired by EnsoData in July 2024.

What Resonea does

Resonea, Inc. was a Delaware-incorporated, Scottsdale-headquartered healthcare technology company that developed sleep testing diagnostic technology aimed at accelerating the diagnosis of sleep disorders, particularly sleep apnea. The company's core offering centered on acoustic flow analysis and microphone data channels that enabled smartphone-based home sleep testing, positioning it to address the widespread underdiagnosis of sleep apnea through a consumer-accessible diagnostic format. The technology leveraged the ubiquity of smartphone microphones to capture respiratory acoustic signatures, eliminating the need for traditional in-lab polysomnography or dedicated hardware for initial screening.

The company operated from approximately 2016 to mid-2024, raising approximately $9.65 million across multiple funding rounds including an initial $4 million round in October 2016, a $250,000 Arizona Commerce Authority grant in January 2018, a $30,000 Flinn Foundation grant in February 2020, a $2.37 million round in September 2020, and a $5 million exempt offering (with $3 million sold) filed via SEC Form D in January 2022. The company was led by CEO Ruchir Sehra and Joe Cooper as Chief of Strategy and Corporate Development, operating with a team of 11-50 employees. Resonea held a US-only operating geography based on its Delaware incorporation and Scottsdale base.

In July 2024, Resonea's sleep testing diagnostic technology — including its acoustic flow analysis and smartphone-based home sleep testing capabilities — was acquired by EnsoData, a US-based healthcare technology and software firm. The transaction represented a technology/asset acquisition rather than an entity acquisition, and the company's website domain subsequently appears to have been repurposed, indicating that Resonea ceased independent operations following the divestiture of its core technology assets to EnsoData.

Resonea firmographics

Firmographics
Name
Resonea
Legal name
Resonea, Inc.
Website
https://resonea.com
Company type
Private
Founded year
2022
Operating status
Acquired
Headcount range
1–10 employees
Short description
Resonea, Inc. was a Scottsdale-based healthcare technology company that developed smartphone-based home sleep apnea diagnostic tools using acoustic flow analysis and microphone data channels. Its core diagnostic technology was acquired by EnsoData in July 2024.
Ownership category
akta.pro rank

Resonea industry classification

Industry
Product category
Sleep Diagnostics Software
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAHAGAB
Sleep Diagnostics & Monitoring (PSG/Home Sleep Testing, Actigraphy)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAHACAL
Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • Sleep apnea diagnostics
  • Home sleep testing
  • Acoustic flow analysis
  • Sleep health technology
  • Digital health screening

Where Resonea is headquartered

Location

Headquarters

HQ city
Scottsdale
HQ country
United States
HQ region
North America

Markets served

Resonea business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations

Resonea product offering

Product offering

Core offering

Resonea developed sleep testing diagnostic technology that enabled home-based sleep apnea screening using acoustic flow analysis and microphone data channels captured via smartphones. The technology was designed to accelerate the diagnosis of sleep disorders and address the widespread underdiagnosis of sleep apnea through accessible, smartphone-enabled home testing rather than traditional in-lab polysomnography.

Product overview

Resonea was a healthcare technology company that developed sleep testing diagnostic technology for sleep apnea screening. The company's primary offering was sleep testing diagnostic technology that utilized acoustic flow and microphone data channels to enable smartphone-based home sleep testing. In July 2024, Resonea's sleep testing technology was acquired by EnsoData, indicating Resonea no longer operates independently in this space.

Differentiator

Problem solved

Functional benefit

Products and services

  • Sleep Testing Diagnostic Technology

Companies that use Resonea

Customer profile

Ideal customer profiles2 records

Resonea technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Resonea partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • EnsoDatanotableTechnology or Integration · 1 July 2024EnsoData, a US-based healthcare technology and software firm, acquired Resonea's sleep testing diagnostic technology in July 2024. The acquisition was intended to enhance EnsoData's sleep apnea screening methods and home sleep testing capabilities through acoustic flow and microphone data channels.

Scale indicators1 record

Recent moves4 records

Expansion highlights2 records

Resonea competitors and assessment

Company assessment

Broad incumbents

  • ResMed: Dominant incumbent in sleep-disordered breathing with CPAP devices, masks, and the myAir platform; an adjacent peer because it influences the diagnostic-to-therapy pathway that any HST technology must integrate with.
  • Philips Sleep & Respiratory Care: Large incumbent offering CPAP, home sleep testing (Alice line), and connected sleep health platforms, providing a broad competitive backdrop for any home-based sleep apnea screening technology.

Direct peers

  • EnsoData: AI-based sleep scoring and diagnostics platform that directly acquired Resonea's acoustic flow technology in 2024 to enhance its home sleep testing offering. Most direct comparable given the asset transfer and overlapping product category.
  • Compumedics: Global sleep diagnostics company offering PSG and home sleep testing systems used in clinical sleep medicine; comparable in product category and end customers.
  • Nox Medical: Manufacturer of the Nox T3 and other home sleep testing/recording systems used by sleep labs and clinicians, making it a direct peer in ambulatory sleep diagnostics hardware.
  • Itamar Medical: Maker of the WatchPAT home sleep apnea testing device. Direct competitor in the home-based sleep apnea diagnostic category with established clinical evidence and regulatory clearances.
  • CleveMed: Provides home sleep testing devices and cloud-based sleep diagnostics services for clinicians, directly competing with Resonea's home-based sleep apnea screening offering.

Emerging players

  • Oura: Smart ring maker whose Oura Ring tracks sleep patterns and has begun exploring chronic condition features; represents the consumer wearable axis that could pressure smartphone-based screening.
  • Withings: Consumer health hardware maker (Sleep Analyzer, ScanWatch) that has moved into home sleep apnea detection, partially overlapping with Resonea's consumer-grade, smartphone-adjacent screening approach.
  • Dreem: Sleep technology company developing EEG-based headbands and digital sleep diagnostics, with overlap in home-based sleep measurement and analytics.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Resonea social profiles

Digital presence

Resonea financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Resonea leadership team

Management profile

Number of profiles

Profiles2 records

Resonea funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Resonea M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Resonea

What does Resonea do?

Resonea developed sleep testing diagnostic technology that enabled home-based sleep apnea screening using acoustic flow analysis and microphone data channels captured via smartphones. The technology was designed to accelerate the diagnosis of sleep disorders and address the widespread underdiagnosis of sleep apnea through accessible, smartphone-enabled home testing rather than traditional in-lab polysomnography.

Is Resonea a public or private company?

Resonea is a private company. It is classified as venture growth investor backed and is currently acquired.

When was Resonea founded?

Resonea was founded in 2022. It employs 1 to 10 people.

Where is Resonea based?

Resonea is headquartered in Scottsdale, United States, in the North America region.

Who are Resonea's main competitors?

Broad incumbents on record are ResMed and Philips Sleep & Respiratory Care. Direct peers are EnsoData, Compumedics, Nox Medical, Itamar Medical and CleveMed. Emerging players are Oura, Withings and Dreem.

Does Resonea have an API?

No public API is recorded for Resonea.

What industry is Resonea in?

Resonea's product category is Sleep Diagnostics Software. Its primary akta.pro industry code is HLAHAGAB, Sleep Diagnostics & Monitoring (PSG/Home Sleep Testing, Actigraphy), with a secondary code of HLAHACAL, Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers). Its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comKey Players and Market Competition in the Sleep Apnea Devices IndustryThe sleep apnea devices market is projected to reach $12.54 billion by 2030, growing at a compound annual growth rate of 8.5%, driven by rising home healthcare services, an aging population, and advancements in sleep monitoring technology. In July 2024, EnsoData, a US-based software company, acquired sleep testing diagnostic technology from Resonea to enhance its sleep apnea screening and diagnosis capabilities. Additionally, in May 2023, US-based Signifier Medical Technologies LLC partnered with Hong Kong-based Sunrise Healthcare Technology to integrate AI-driven solutions with Signifier's daytime sleep apnea therapy device eXciteOSA.openPR.comKey Factors and Emerging Trends Shaping the Positive Air Pressure Devices Market LandscapeThe positive air pressure devices market is projected to grow to $4.47 billion by 2030, representing a compound annual growth rate of 7.2%, driven by AI integration in respiratory monitoring, tele-respiratory care expansion, and increasing demand from an aging population. In July 2024, US-based healthcare technology firm EnsoData acquired sleep-testing diagnostic technology from Resonea to enhance home sleep testing capabilities through acoustic flow and microphone data channels. In February 2024, ResMed launched the AirCurve 11 Bilevel Devices featuring dual pressure settings, integrated humidification, and wireless connectivity for remote monitoring of sleep apnea, COPD, and respiratory disorders.openPR.comLeading Companies Consolidating Their Presence in the Home Sleep Screening Devices MarketThe home sleep screening devices market is projected to reach $6.22 billion by 2030, growing at a compound annual growth rate of 9.9%, driven by AI integration in sleep monitoring, an aging population, and rising demand for wearable health devices. In July 2024, EnsoData, Inc. acquired sleep testing technology from Resonea to enhance acoustic flow analysis and smartphone-based diagnostics for sleep apnea. In April 2025, ResMed launched the FDA-cleared NightOwl, a disposable fingertip-worn device that records sleep data for up to ten nights, offering a convenient home-based alternative for obstructive sleep apnea diagnosis.openPR.comFuture Perspective: Key Trends Shaping the Sleep Tech Devices Market Up to 2030The Business Research Company released a market report forecasting the global sleep tech devices market to reach $57.47 billion by 2030, growing at a compound annual growth rate of 18.0%, driven by personalized health technologies, digital sleep therapy adoption, and AI-powered innovations. In July 2024, US-based software firm EnsoData acquired Resonea's sleep testing technology to enable smartphone-based sleep apnea screening at home, addressing the condition's widespread underdiagnosis. Additionally, Indian furniture company Wakefit launched its Zense product line in June 2024, introducing India's first AI-powered sleep aids with temperature regulation capabilities.SleepworldmagazineEnsoData Acquires Resonea Sleep Testing Diagnostic TechnologyEnsoData has acquired sleep testing diagnostic technology from Resonea to enhance its platform with acoustic flow and microphone data channels for pre-screening sleep apnea. This acquisition enables the use of an FDA-cleared mobile application on existing smartphones to record and analyze respiratory data, expanding diagnostic capabilities beyond traditional methods. Initial US commercial availability for these new capabilities is expected within 2024.MadisonstartupsEnsoData Acquires Technology from Resonea - Startup and Tech News - Madison StartupsEnsoData has acquired sleep testing diagnostic technology from Resonea to reduce costs for addressing sleep apnea in large patient populations. The acquisition adds acoustic flow and microphone data channels to EnsoData's FDA-cleared mobile application, expanding pre-screening capabilities for home sleep testing. These new features are expected to be available later this year.SecSEC FORM DResonea, Inc. filed a Form D with the U.S. Securities and Exchange Commission to report an exempt offering of equity securities under Rule 506(b). The company disclosed a total offering amount of $5 million, with $3 million already sold to one investor as of January 7, 2022.PR NewswireRESONEA Obtains FDA Clearance for Smartphone-Based In-Home Screening for Obstructive Sleep ApneaResonea, Inc. received 510(k) clearance from the US Food and Drug Administration (FDA) for its DROWZLE Sleep Apnea Pre-screening Device, a smartphone-based software tool designed for in-home screening of obstructive sleep apnea. The device utilizes proprietary algorithms to analyze respiratory patterns recorded via iPhone, achieving a 93.7% sensitivity rate in detecting moderate to severe cases during clinical studies. This regulatory approval enables the commercialization of the prescription Class II medical device to assist healthcare professionals in determining the need for further diagnosis.